An AI tool can distinguish histological remission from activity in biopsies of UC and predict flare-ups and could have a role in both clinical trials and routine practice.
Data from a retrospective study support histologic remission to predict relapse-free survival in patients with ulcerative colitis (UC) whose disease is in remission.